Full Generic Medicine Info
Dosage/Direction for Use

Dysfunctional uterine bleeding
Adult: 60 mg twice a wk for the 1st 12 wk and then 60 mg once a wk for up to next 12 wk.

Adult: Take 1 tablet (30 mg) twice a wk for the 1st 12 wk then 1 tablet (30 mg) once a wk from 13th wk onwards. Take 1st tablet on the 1st day of menstrual cycle. Follow dose irrespective of menstrual periods.
Polycystic ovarian disease, cervical hyperplasia, recent history of jaundice or hepatic impairment, severe allergic states, TB, renal impairment. Pregnancy and lactation.
Special Precautions
Women who desire to be pregnant should discontinue taking the drug.
Adverse Reactions
Delayed menses.
Ormeloxifene acts on oestrogen receptors. It has a weak estrogenic and potent antiestrogenic actions. It is expected to exert a contraceptive effect and normalise the bleeding from uterine cavity by regularising the expression of oestrogen receptors on the endometrium. As a contraceptive, it prevents proliferation and decidualisation of the endometrium, enhances blastocyst formation and slightly increases embryo transport through the oviducts.
Absorption: Well absorbed from the GI tract. Peak serum levels achieved in 4 hr.
Distribution: Widely distributed in tissues. Little affinity to plasma proteins.
Excretion: Terminal half-life: Approx 170 hr.
CIMS Class
Drugs Acting on the Uterus / Oral Contraceptives
ATC Classification
G03XC04 - ormeloxifene ; Belongs to the class of selective estrogen receptor modulators.
Disclaimer: This information is independently developed by CIMS based on ormeloxifene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in